Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $257,577 | $989,691 | $2,457,619 | $1,045,606 |
| - Cash | $77,391 | $170,201 | $62,526 | $50,191 |
| + Debt | $1,981 | $4,237 | $6,277 | $0 |
| Enterprise Value | $182,167 | $823,727 | $2,401,370 | $995,415 |
| Revenue | $87,371 | $380,786 | $22,230 | $0 |
| % Growth | -77.1% | 1,612.9% | – | – |
| Gross Profit | $45,215 | $355,345 | $19,237 | $0 |
| % Margin | 51.8% | 93.3% | 86.5% | – |
| EBITDA | -$290,976 | $39,890 | -$200,854 | -$82,636 |
| % Margin | -333% | 10.5% | -903.5% | – |
| Net Income | -$301,743 | $49,271 | -$198,375 | -$87,931 |
| % Margin | -345.4% | 12.9% | -892.4% | – |
| EPS Diluted | -4.43 | 0.7 | -2.98 | -1.52 |
| % Growth | -732.9% | 123.5% | -96.1% | – |
| Operating Cash Flow | -$167,647 | $11,919 | -$179,871 | -$74,799 |
| Capital Expenditures | -$157 | -$1,241 | -$2,526 | -$353 |
| Free Cash Flow | -$167,804 | $10,678 | -$182,397 | -$75,152 |